Skip to main content
Canna~Fangled Abstracts

Neuroprotective potential of Cannabis sativa-based oils in Caenorhabditis elegans

By September 14, 2022No Comments

. 2022 Sep 13;12(1):15376.

doi: 10.1038/s41598-022-19598-3.

Ana Paula Vanin 1, Wagner Antonio Tamagno 2 3, Carla Alves 3 4, Letícia Mesacasa 5, Luciani Figueiredo Santin 3, Nathália Tafarel Sutorillo 3, Denise Bilibio 3, Caroline Müller 6, Leandro Galon 1, Rosilene Rodrigues Kaizer 1 3
Affiliations 

Abstract

Substances from the Cannabis sativa species, especially cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (Δ9-THC), have attracted medical attention in recent years. The actions of these two main cannabinoids modulate the cholinergic nervous system (CholNS) involving development, synaptic plasticity, and response to endogenous and environmental damage, as a characteristic of many neurodegenerative diseases. The dynamics of these diseases are mediated by specific neurotransmitters, such as the GABAergic nervous system (GNS) and the CholNS. The nematode Caenorhabditis elegans is an important experimental model, which has different neurotransmitter systems that coordinate its behavior and has a transgene strain that encodes the human β-amyloid 1-42 peptide in body wall muscle, one of the main proteins involved in Alzheimer´s disease. Therefore, the objective of this study was to evaluate the protective potential of terpenoids found in C. sativa in the GNS and CholNS of C. elegans. The effect of two C. sativa oils with variations in CBD and THC concentrations on acetylcholinesterase (AChE) activity, lipid peroxidation, and behavior of C. elegans was evaluated. C. sativa oils were efficient in increasing pharyngeal pumping rate and reducing defecation cycle, AChE activity, and ROS levels in N2 strains. In the muscle:Abeta1-42 strain, mainly when using CBD oil, worm movement, body bends, and pharyngeal pumping were increased, with a reduced AChE activity. Consequently, greater investments in scientific research are needed, in addition to breaking the taboo on the use of the C. sativa plant as an alternative for medicinal use, especially in neurodegenerative diseases, which have already shown positive initial results.

References

    1. Andre, C. M., Hausman, J. F. & Guerriero, G. Cannabis sativa: The plant of the thousand and one molecules. Front. Plant Sci. 7, 19 (2016). – PubMed – PMC – DOI
    1. Crippa, J. A., Guimarães, F. S., Campos, A. C. & Zuardi, A. W. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front. Immunol. 9, 1256–1265 (2018). – DOI
    1. Martínez, V. et al. Cannabidiol and other non-psychoactive cannabinoids for prevention and treatment of gastrointestinal disorders: Useful nutraceuticals?. Int. J. Mol. Sci. 21, 3067 (2020). – PMC – DOI
    1. Lu, H. C. & Mackie, K. An introduction to the endogenous cannabidiol system. Biol. Psychiatry 79, 516–525 (2016). – PubMed – DOI
    1. Thomas, A. et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150, 613–623 (2007). – PubMed – PMC – DOI

Leave a Reply